Trial
NCT02913508
Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Vedolizumab intravenous injection
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-09-23